Investigating the Root Cause of Cancer
Huiping Liu, MD, PhD, associate professor of Pharmacology, studies cancer stem cells and how they can be used to create new therapies that eradicate the root cause of cancers.Watch this video
Cancer pharmacology is the study of the molecular and cellular mechanisms of cancer cells and the identification of novel therapeutic targets and treatment strategies. Faculty in the department study basic mechanisms responsible for cancer and its spread (metastasis) with the goal of finding new molecular targets for destroying cancer cells. An emphasis on difficult to treat breast cancer subtypes, which includes research on cancer stem cells, is leading to discoveries of new disease mechanisms and drug targets.
Dai Horiuchi, PhD, assistant professor of Pharmacology, and his team are devoted to understanding the cellular events that influence the aggressive of breast tumors and discovering new therapeutic strategies to treat those tumors.Watch this video
Daniel Martin Watterson, PhD, professor of pharmacology and John G. Searle Professor of Molecular Biology and Biochemistry, studies biological mechanisms important in how cells communicate with each other. The work is advancing basic and translational knowledge about critical biological processes and molecules that regulate physiological pathways, and how they are altered in diseases such as Alzheimer’s disease, brain injury and cancer. The goal is to develop novel drug treatments that can intervene in disease progression.
Investigating the application of human induced pluripotent stem cells to study the pharmacogenomics of chemotherapy off-target toxicity and efficacy
The Burridge lab studies the role of the genome in influencing drug responses, known as pharmacogenomics or personalized medicine. Our major model is human induced pluripotent stem cells (hiPSC), generated from patient's blood or skin. We use a combination of next generation sequencing, automation and robotics, high-throughput drug screening, high-content imaging, tissue engineering, electrophysiological and physiological testing to better understand the mechanisms of drug response and action.
Our major effort has been related to patient-specific responses to chemotherapy agents. We ask the question: what is the genetic reason why some patients have a minimal side effects to their cancer treatment, whilst others have encounter highly detrimental side-effects? These side-effects can include cardiomyopathy (heart failure or arrhythmias), peripheral neuropathy, or hepatotoxicity (liver failure). It is our aim to add to risk-based screening by functionally validating genetic changes that predispose a patient to a specific drug response.
See Dr. Burridge's publications on PubMed.
Contact Dr. Burridge at 312-503-4895.
Transcriptional and Epigenetic Regulatory Mechanisms in Nuclear Hormone Signaling and Cancer Cell Function
The Chakravarti laboratory is interested in understanding the roles of nuclear hormone signaling and epigenetic modifications in regulating normal cell and organ physiology and how altered transcriptional and epigenetic signaling contributes to cancer development and metastasis. To pursue these overall goals, we are currently focusing on three research areas which are of significant current interests in biomedical field.
Research Area 1: Transcriptional Regulation of Tumor Development: Cancer is a complex disease and remains poorly understood. In particular, how altered transcriptional and epigenetic regulation contributes to cancer development and progression is not clear. We have recently discovered and characterized a new family of proteins termed the THAP family. Using xenograft mouse model, next generation mRNA and ChIP deep sequencing, extensive analysis of human progressive cancer tissue samples and state-of-the-art molecular techniques, members of the laboratory are determining the role of this novel THAP domain transcription factor and its cofactor HCF1 in cell cycle regulation and cancer progression. These studies should advance our knowledge of cancer progression and may provide a molecular target for therapeutic intervention.
Research Area 2: Nuclear Hormone Receptor Signaling in Physiology and Uterine Fibrosis: Alterations of receptor/hormone function and coactivator and corepressor proteins have been implicated in several human diseases including cancer and fibrotic diseases. We are currently determining the role of epigenetic changes and novel cofactors in hormone signaling and prostate and breast cancer. Tissue fibrosis is a major health problem in the world. We have profiled all 48 human nuclear receptors in uterine fibroids and found profound changes of receptor expression in normal and fibroid uterine tissues. Laboratory members are currently using biochemical, bioinformatics, ChIP, deep sequencing and molecular techniques to determine epigenetic cross talk in hormone signaling and human cancer and uterine fibroids.
Research Area 3: Epigenetic Modifications and Effectors of Chromatin Function: Combinatorial histone modifications including acetylation, methylation and phosphorylation play important regulatory roles in gene expression, chromatin function and cell cycle progression. We have recently demonstrated that the SR-proteins are critical cell cycle-dependent effector proteins for histone H3 serine 10 phosphorylation. We are also determining the role of histone H3 T11 phosphorylation and its effector protein WDR5 in androgen receptor function and in prostate cancer. Members in the laboratory are currently investigating the mechanisms by which these “effector-modification” interactions contribute to cell cycle progression and human diseases including cancer.
For more information, please see, visit the Dr. Chakravarti's faculty profile.
See Dr. Chakravarti's publications in PubMed.
Editorial Board: Molecular Endocrinology 2011- present, Mol. Cell. Biol. 2014-2017
The Editor of a Book volume on “Regulatory Mechanisms in Transcriptional Signaling” in Progress in Molecular Biology and Translational Science (Vol 87), published in Aug 2009, Academic Press, Chakravarti, D. Editor
Contact Chakravarti lab at 312-503-0782, 312-503-0783 or 312-503-0784. Our fax is 312-503-0095.
Investigating of the mechanistic connection between aging, cellular and/or mitochondrial metabolism and carcinogenesis with specific focus on the Sirtuin gene family.
Human sirtuins are the human homologs for the yeast and C. elegans longevity genes and breast cancers have one of the strongest correlations to age. Having this information, it is proposed that the primary sirtuin family knockout mice may present a novel group of models to establish, validate and investigate the well-established connection between aging, metabolism and cancer. To address this idea, over the past five years, we have constructed mice that have the three primary (Sirt1-3) sirtuins genetically deleted.
These each develop breast cancer, as well as other types of malignancies to varying degrees, and the levels of SIRT1-3 are also decreased in human cancer samples, as compared to normal tissues. In addition, the mechanism connecting the tumor permissive phenotype and the aberrant regulation of mitochondrial ROS, at least in part, in the Sirt3 knockout mouse has recently been published. Based on these results it seems clear that the primary sirtuin deacetylase proteins are tumor suppressor in several breast cancers as well as to a lesser extent in several other human malignancies.
Currently, our lab is utilizing the murine in vivo and in vitro models in several different projects examining the interactions of Sirt2 with proteins KRas, PKM2 and P53. We are also pursuing the efficacy of chemopreventive agents in luminal B breast malignancies. In addition we are studying the mechanistic link connecting Sirt2 and Sirt3 to cancers of the breast, pancreas, liver and lung. Finally, we have a group of neuroscientists examining the potential role of sirtuins in the development of neurodegenerative diseases that are associated with aging, particularly Parkinson’s.
For lab information and more, see David Gius', MD,PhD, faculty profile.
See Dr. Gius' publications in PubMed.
Contact the Gius Lab at 312-503-0332. You may also contact Dr. Gius directly at 312-503-2053 or via email.
Understanding the cellular events that influence the aggressiveness of tumors and patient clinical outcome
The major focus of the Horiuchi lab, established on April 1, 2015, is on the mechanisms of tumor maintenance and progression in breast cancer and to identify novel therapeutic targets and treatment strategies. To achieve these goals, we utilize a collection of human breast cancer cell lines, preclinical animal models and high-throughput screening approaches along with state-of-the-art bioinformatics through collaboration with experts in the field.
We are currently focused on the following areas:
For lab information and more, see Dr. Horiuchi’s faculty profile.
See Dr. Horiuchi's publications on PubMed.
Contact Dr. Horiuchi at 312-503-4085 or the lab at 312-503-4349.
Dissecting the regulation of gene transcription and RNA translation underlying oncogenic processes.
Cancer happens through accumulated genetic mutations and epigenetic alternation in normal cells. With the advances of genomic technologies, we now can precisely characterize the genome-wide alternations of gene expression underlying oncogenic processes in a cost-effective and unbiased manner. My lab will use the combined experimental genomic technologies and computational modeling to examine the regulation of gene transcription and RNA translation during steps of oncogenesis. We aim at revealing novel cancer therapeutic targets and strategies for precision medicine and immunotherapy.
Currently, we are working on the following projects.
For lab information and more, see Dr. Ji's faculty profile.
See Dr. Ji's publications on PubMed.
Contact Dr. Ji at 312-503-2187.
Investigating the roles of cell cycle-regulatory proteins in differentiation, senescence and tumorigenesis and the cell cycle control in endocrine and reproductive organs
We are interested in the basic mechanisms of cell cycle control, cellular senescence/immortalization and malignant transformation, with a focus on protein regulation by ubiquitination. We previously demonstrated that cell cycle regulators such as p27Kip1, CDK4 and CDC25A play highly tissue-specific roles in development and oncogenesis. Ubiquitination, the covalent modification of substrate proteins with the small 76-residue protein ubiquitin, exerts diverse regulation of the fate of substrates, including the cell cycle regulators, e.g, promoting proteolysis, altering subcellular localization and modulating enzymatic activities. Our current research is aimed at revealing novel functions of ubiquitination enzymes and their substrates in development and cancer, which is expected to identify new therapeutic targets against human diseases. The laboratory uses a combination of protein engineering, proteomics, bioinformatics, cell biological techniques such as time-lapse microscopy and 3-D culture and genetically engineered mouse models. Keywords: cell cycle, ubiquitin, ubiquitination, cancer initiation, cancer progression, knockout mice, transgenic mice, breast cancer, cyclin, diabetes, pituitary, development.
We are currently investigating roles of the cell cycle machinery in differentiation, tumorigenesis and apoptosis, by combinations of mouse models and molecular analyses.
For lab information and more, see Dr. Kiyokawa’s faculty profile.
See Dr. Kiyokawa's publications on PubMed.
Contact Dr. Kiyokawa 312-503-0699.
Understanding and targeting cancer stem cells and exosomes in metastasis using cutting-edge technology and novel therapeutics
The Liu lab studies the molecular and cellular mechanisms underlying cancer stem cells (CSCs) and metastasis through four ongoing interactive basic and translational research projects: (1) to understand CSCs, circulating tumor cells (CTCs) and their interactions with immune cells in metastasis; (2) to dissect the role of secreted and circulating exosomes in CSC functions; (3) to target CSCs with novel therapeutics, exosomes and nanoparticles in combination with immunotherapy; (4) to develop CTC and circulating exosome-based biomarkers for cancer diagnosis, therapy response and predictive prognosis.
See Dr. Liu's publications on PubMed.
Contact Dr. Liu at 312-503-5248.
Defining the molecular mechanisms of breast tumor initiation, progression, and metastasis, and identifying novel targets for therapeutic development.
Posttranslational modifications such as ubiquitination, methylation, ADP-ribosylation as well as phosphorylation orchestrate genome stability, cell division, hormone-initiated signal transduction, apoptosis and tumorigenesis. Posttranslational modifications act as critical molecular switches or fine-tune operators that determine the activation, deactivation or subcellular localization of functional proteins. Emerging evidence has drawn attention to the modulation of regulatory proteins in response to extrinsic/intrinsic signaling being executed simultaneously by multiple posttranslational modifications. Research interests in my laboratory seek to address how defects in the ubiquitin-proteasome system (E3 ligase/deubiquitinase), protein methyltransferase and poly (ADP-ribose) polymerase 1 (PARP1) would result in genomic instability, abnormal cell cycle or apoptosis, and aberrant signal transductions (e.g., ER, TGF-β, EGFR and Hippo) that predispose otherwise normal cells to become cancerous tumor cells. The ultimate objective is to integrate our basic research with clinical translational studies that would allow the development of new anti-cancer therapy thereby fully exploiting our knowledge of posttranslational modifications. To achieve our goals, we have developed a multidisciplinary approach that includes biochemical, cell biological, genetic, protein structural analyses as well as the use of animal models and analyses of clinical specimens.
See Dr. Wan's publications on PubMed.
Contact Dr. Wan at 312-503-2769.